Ascendis Pharma A/S

Ascendis Pharma Misses on EPS, Stock Down 2.72%

Ascendis Pharma reported a larger-than-expected loss per share for Q2 2024, which contributed to a 2.72% decline in its stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future prospects. Overall, the market reacted negatively to the earnings report, reflecting uncertainty about the company's direction.